Holy cow is CLSN getting destroyed. That's the life and risk of investing in a biotech company. The great thing about MNKD and Afressa is that we know the drug works from previous trials with very little concernable short term side affects. The questions are, 1) Is Afrezza as good if not better than standard treatment and 2) does the new device work effectively in delivering accurate and measured doses vs the old inhaler.

I don't think we will see the same PPS rise with MNKD due to the history of MNKD and Al Mann. MNKD has baked into itself a flavor of mistrust with the street imho.